Docetaxel administered on a weekly basis for metastatic breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1212-1219

  Burstein, Harold J ^a   Manola, Judith ^a   Younger, Jerry ^a   Parker, Leroy M ^a   Bunnell, Craig A ^a   Scheib, Rochelle ^a   Matulonis, Ursula A ^a   Garber, Judy E ^a   Clarke, Kathryn D ^a   Shulman, Lawrence N ^a   Winer, Eric P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONJUNCTIVITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; FATIGUE; FEMALE; HUMAN; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034061842     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1212     Document Type: Article

References (33)

1. Chevallier B, Fumoleau P, Kerbat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II study of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314-322, 1995
2. Hudis CA, Seidman AD, Crown JPA, et al: Phase II and pharmacological study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65, 1996
3. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428, 1996
4. Ravdin PM, Burris HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995
5. Valero V, Holmes FA, Walters RS, et al: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894, 1995
6. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
7. Piccart MJ, Klijn J, Paridaens R, et al: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15:3149-3155, 1997
8. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the clinical screening group of the EORTC. Br J Cancer 74:650-656, 1996
9. O'Brien MER, Leonard RCF, Barrett-Lee PJ, et al: Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 10:205-210, 1999
10. Archer CD, Lowdell C, Sinnett HD, et al: Docetaxel: Response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer 34:816-819, 1998
11. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy: A phase II single-center study. J Clin Oncol 17:1127-1131, 1999
12. Nabholtz JM, Gelman K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
13. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 388)
14. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998
15. Klaasen U, Wilke H, Strumberg D, et al: Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A:547-549, 1996
16. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacological study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15;187-192, 1997
17. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458-1467, 1994
18. Hainsworth JD, Burris HA, Erland JB, et al: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168, 1998
19. Löffler TM, Freund W, Droge C, et al: Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:113a, 1998 (abstr 435)
20. Briasoulis E, Karavasilis V, Anastasopoulos D, et al: Phase I trial of weekly administration of docetaxel in minimally pretreated cancer patients: A feasibility and cumulative toxicity study. Ann Oncol 9:101, 1998 (abstr 385, suppl 2)
21. Hryniuk WM, Goodyear M: The calculation of received dose intensity. J Clin Oncol 8:1935-1937, 1990
22. Fumoleau P, Chevallier B, Kerbrat P, et al: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996
23. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999
24. Nabholz JM, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel verus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyline-containing chemotherapy. J Clin Oncol 17:1413-1424, 1999
25. Sjöström J, Blomqvist C, Mouridsen H, et al: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194-1201, 1999
26. Adachi I, Watanabe T, Takashima S, et al: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent cancer. Br J Cancer 73:210-216, 1996
27. Ten Bokkel Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC early clinical trials group. Ann Oncol 5:527-532, 1994
28. Archer CD, Lowdell C, Sinnett HD, et al: Docetaxel: Response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J Cancer 34:816-819, 1998
29. Climent CA, Ruiz A, Llombart-Cusac A, et al: Weekly docetaxel in patients with advanced malignancies: Toxicity profile and activity results. Proc Am Soc Clin Oncol 18:119a, 1999 (abstr 453)
30. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F: Docetaxel (Taxotere): A review of preclinical and clinical experience - Part I: Preclinical experience. Anticancer Drugs 6:339-368, 1995
31. Perez EA: Paclitaxel in breast cancer. The Oncologist 3:373-389, 1998
32. Perez EA, Irwin DH, Patel R, et al: A large phase II trial of paclitaxel administered as a weekly one hour infusion to patients with metastatic breast cancer. Proc Am Soc Clin Oncol 18:126a, 1999 (abstr 480)
33. Norton L: Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 26:11-20, 1999 (suppl 2)